CD79A and respiratory tract infectious disorder: Studies have suggested that vaccination regimens capable of inducing strong mucosal immune responses, including local IgA and tissue-resident cellular immunity, may be more effective in preventing respiratory infections, including SARS-CoV-2 infection24–27.